...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Die Pharmazie >Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients
【24h】

Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients

机译：甲状腺激素状态和同时用药对他汀类药物引起的高血脂患者不良反应的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Statins are effective treatment for the prevention of cardiovascular diseases and used extensively worldwide. However, adverse effects induced by statins are the major barrier of maximalizing cardiovascular risk reduction. Hypothyroidism and administration of drugs metabolized on the same cytochrome P450 (CYPP450) pathways where statin biotransformation occurs represent a significant risk factor for statin induced adverse effects including myopathy. Simvastatin, atorvastatin and lovastatin are metabolized by CYP3A4, fluvastatin by CYP2C9, while rosuvastatin by CYP2C9 and 2C19. We investigated the levels of the free thyroid hormones and CYP metabolism of concomitant medication in 101 hyperlipidemic patients (age 61.3 ± 9.9 ys) with statin induced adverse effects including myopathy (56 cases; 55.4%), hepatopathy (39 cases; 38.6%) and gastrointestinal adverse effects (24 cases; 23.8%). Abnormal thyroid hormone levels were found in 5 patients (4.95%); clinical hypothyroidism in 2 and hyperthyroidism in 3 cases. 11 patients had a positive history for hypothyroidism (10.9%). Myopathy occured in one patient with hypothyroidism and two patients with hyperthyroidism. There were no significant differences in the TSH, fT4 and fT3 levels between patients with statin induced myopathy and patients with other types of adverse effects. 78 patients (77.2%) were administered drugs metabolized by CYP isoforms also used by statins (3A4: 66 cases (65.3%); 2C9: 67 cases (66.3%); 2C19: 54 cases (53.5%)). Patients with myopathy took significantly more drugs metabolized by CYP3A4 compared to patients with other types of adverse effects (p < 0.05). Moremyopathy caseswere found in patients on simvastatin treatment (52% vs. 38%, ns.), while significantly less patients with myopathy were on fluvastatin treatment (13% vs. 33%, p < 0.05) compared to patients with other types of statin induced adverse effects. Both abnormal thyroid hormone status and administration of drugs metabolized by CYP3A4, 2C9 and 2C19 are common in our patients with statin induced adverse effects. Normalizing the thyroid hormone status and optimizing of the concomitant medication may reduce the risk of statin induced adverse effects.
机译：他汀类药物是预防心血管疾病的有效方法，在全世界范围内广泛使用。但是，他汀类药物引起的不良反应是最大程度地降低心血管疾病风险的主要障碍。甲状腺功能减退症和在发生他汀类药物生物转化的相同细胞色素P450（CYPP450）途径上代谢的药物的给药，是他汀类药物引起的不良反应（包括肌病）的重要危险因素。辛伐他汀，阿托伐他汀和洛伐他汀被CYP3A4代谢，氟伐他汀被CYP2C9代谢，瑞舒伐他汀被CYP2C9和2C19代谢。我们调查了101例他汀类药物引起的不良反应的高脂血症患者（包括肌病（56例; 55.4％），肝病（39例; 38.6％）和胃肠道不良反应（24例; 23.8％）。 5例患者中甲状腺激素水平异常（4.95％）;临床甲状腺功能减退2例，甲状腺功能亢进3例。 11例甲状腺功能减退阳性史（10.9％）。肌病发生在一名甲状腺功能低下的患者和两名甲状腺功能亢进的患者。他汀类药物致肌病患者与其他类型不良反应患者之间的TSH，fT4和fT3水平无显着差异。 78例患者（77.2％）接受了他汀类药物也通过CYP亚型代谢的药物（3A4：66例（65.3％）; 2C9：67例（66.3％）; 2C19：54例（53.5％））。与具有其他类型不良反应的患者相比，患有肌病的患者服用经CYP3A4代谢的药物要多得多（p <0.05）。在辛伐他汀治疗的患者中发现了更多的肌病病例（52％对38％，ns）。而与其他类型的他汀类药物治疗的患者相比，接受氟伐他汀治疗的肌病患者明显减少（13％对33％，p <0.05）引起的不良反应。在他汀类药物诱发的不良反应患者中，甲状腺激素状态异常和经CYP3A4、2C9和2C19代谢的药物的给药都很常见。使甲状腺激素状态正常化并优化伴随用药可能会降低他汀类药物引起的不良反应的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号